Quick Answer
RIGEL PHARMACEUTICALS INC reported Operating Income Loss of $125.47 million for the year ending 2025.
- RIGEL PHARMACEUTICALS INC showed an increase of +418.6% in Operating Income Loss from 2024 to 2025.
- This data is from RIGEL PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), RIGEL PHARMACEUTICALS INC's Operating Income Loss has grown by 212.0%.
- Historical annual values: Fiscal year 2025: $125.47 million | Fiscal year 2024: $24.19 million | Fiscal year 2023: -$20.49 million | Fiscal year 2022: -$55.55 million | Fiscal year 2021: -$12.50 million | Fiscal year 2020: -$28.97 million | Fiscal year 2019: -$69.09 million | Fiscal year 2018: -$72.68 million | Fiscal year 2017: -$79.62 million | Fiscal year 2016: -$69.74 million | Fiscal year 2015: -$51.74 million | Fiscal year 2014: -$91.25 million | Fiscal year 2013: -$89.47 million | Fiscal year 2012: -$99.38 million | Fiscal year 2011: -$86.37 million | Fiscal year 2010: $35.32 million | Fiscal year 2009: -$112.04 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: